PRICING-PRESCRIPTION INSULIN

Amends the Comprehensive Health Insurance Plan Act. Makes a technical change in a Section concerning the short title. Senate Floor Amendment No. 2 Deletes reference to: 215 ILCS 105/1 Adds reference to: 5 ILCS 375/6.11 15 ILCS 205/10 new 55 ILCS 5/5-1069.3 65 ILCS 5/10-4-2.3 105 ILCS 5/10-22.3f 215 ILCS 5/356w 215 ILCS 5/356z.41 new 215 ILCS 125/5-3 from Ch. 111 1/2, par. 1411.2 215 ILCS 130/4003 from Ch. 73, par. 1504-3 215 ILCS 165/10 from Ch. 32, par. 604 Replaces everything after the enacting clause. Amends the Attorney General Act. Provides that the Attorney General shall investigate the pricing of prescription insulin drugs to ensure adequate consumer protections for Illinois consumers and to determine whether additional consumer protections are necessary. Requires the Attorney General to make the findings available to the public and to report to the Governor, the Department of Insurance, and to the Judiciary Committees of the Senate and the House of Representatives. Provides for the repeal of the Attorney General's investigative duties on December 31, 2020. Amends the Illinois Insurance Code. Provides that insurers that provide coverage for prescription insulin drugs must limit the total amount an insured is required to pay for a covered prescription insulin drug to $100 per 30-day supply of insulin regardless of the type and amount of insulin needed by the insured. Provides that the limitation on insulin costs also applies to provisions requiring coverage of certain diabetes items to be subject to the same coverage, deductible, co-payment, and co-insurance provisions under a policy. Makes conforming changes in the State Employees Group Insurance Act of 1971, the Counties Code, the Illinois Municipal Code, the School Code, the Health Maintenance Organization Act, the Limited Health Service Organization Act, and the Voluntary Health Services Plans Act. Effective January 1, 2021, except that changes to the Attorney General Act take effect immediately. Senate Floor Amendment No. 3 In provisions amending the Illinois Insurance Code concerning cost sharing in prescription insulin drugs, provides that the definition of "prescription insulin drug" does not include an insulin drug that is administered to a patient intravenously. House Committee Amendment No. 1 Adds reference to: 5 ILCS 375/6.11 55 ILCS 5/5-1069.3 65 ILCS 5/10-4-2.3 105 ILCS 5/10-22.3f 215 ILCS 5/356w 215 ILCS 5/356z.41 new 215 ILCS 5/356z.42 new 215 ILCS 125/5-3 from Ch. 111 1/2, par. 1411.2 215 ILCS 130/4003 from Ch. 73, par. 1504-3 215 ILCS 165/10 from Ch. 32, par. 604 Replaces everything after the enacting clause. Reinserts the bill as engrossed with the following changes: Removes provisions amending the Attorney General Act. Requires the Department of Insurance in conjunction with the Department of Human Services and the Department of Healthcare and Family Services shall make available to the public a report that details each Department's findings regarding insulin pricing practices and variables that contribute to pricing of health coverage plans, and public policy recommendations to control and prevent overpricing of prescription insulin drugs made available to Illinois consumers by November 1, 2020. Effective January 1, 2021, except that provisions requiring an insulin pricing report take effect immediately.